MedTrace Logo

H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection

NCT00926809 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2009-06-25

No results posted yet for this study

Summary

This study will evaluate the effect of Helicobacter pylori eradication therapy on the healing of iatrogenic gastric ulcer caused by endoscopic mucosal resection of gastric neoplastic lesions and is a multicenter, randomized, double blind, and placebo controlled trial.

Conditions

  • Ulcer

Interventions

DRUG

Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin

Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg

DRUG

Lansoprazole (proton pump inhibitor), placebo

Lansoprazole, Amoxicillin placebo, Clarythromycin placebo

Sponsors & Collaborators

  • Korean College of Helicobacter and Upper Gastrointestinal Research

    lead OTHER

Principal Investigators

  • Hyun Chae Jung · Korean College of Helicobacter and Upper Gastrointestinal Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-09-30
Completion
2010-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00926809 on ClinicalTrials.gov